| 本文已被：浏览 367次 下载 310次 |
码上扫一扫！ |
| 奥司他韦相关儿童神经精神系统不良反应的文献分析 |
| 雷珍珍1,芮薇1,马明月1,马昊1,刚瑛1,彭硕1,孙洪利1,林盈达1,林志健2,张文想1 |
| (1. 北京中医药大学东直门医 院,北京 100700;2. 北京中医药大学,北京 102488) |
|
| 摘要: |
| 目的:分析奥司他韦诱发儿童神经精神系统药物不良反应(ADR)的临床特征,为儿科临床安全用药提供参考。 方法:检 索中国知网、万方及 PubMed 数据库,检索时限为建库至 2025 年 9 月 1 日,筛选奥司他韦相关神经精神系统 ADR 病例报道,统 计分析性别、年龄、ADR 发生时间及转归等指标。 结果:共纳入 15 篇文献(10 篇国内、5 篇国外),涉及 18 例患儿,男女各 9 例, 年龄(8. 35±5. 34)岁。 66. 67%的病例因流感用药,其中 2 例存在用药不规范(1 例为 2 个月婴儿用于治疗,1 例为 9 岁儿童用于 预防)。 83. 33%的 ADR 发生于用药后<3 d,主要表现为睡眠障碍、易哭闹、烦躁、谵妄,严重者出现自杀念头及自伤行为;多数 病例停药后 3 d 内症状缓解。 结论:临床使用奥司他韦时,应强化用药后 2 d 内神经精神症状监测,尤其需关注患儿潜在自杀风 险。 出现神经精神系统 ADR 需立即停药;若未缓解或加重,应立即就医。 同时需加强监护人用药教育。 |
| 关键词: 奥司他韦 神经精神系统 药物不良反应 儿童 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2026.06.012 |
|
| 基金项目:中国毒理学会临床毒理专项(2020 年度)课题,编号 CST2020CT101 |
|
| Literature Analysis on Neuropsychiatric Adverse Drug Reactions in Children Associated with Oseltamivir |
| Lei Zhenzhen1 , Rui Wei1 , Ma Mingyue1 , Ma Hao1 , Gang Ying1 , Peng Suo1 , Sun Hongli1 , Lin Yingda1 , Lin Zhijian2 , Zhang Wenxiang1 |
| (1. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China; 2. Beijing University of Chinese Medicine, Beijing 102488, China) |
| Abstract: |
| Objective: To analyze the clinical characteristics of oseltamivir-induced neuropsychiatric adverse drug reactions (ADR) in children, and to provide reference for safe medication in children. Methods: CNKI, Wanfang, and PubMed databases were retrieved from database establishment to Sept. 1st, 2025. Case reports of oseltamivir-induced neuropsychiatric ADR were screened, with statistical analysis performed on gender, age, ADR onset time, and outcomes. Results: Fifteen studies ( 10 domestic studies, 5 international studies) including 18 patients were enrolled. There were 9 males and 9 females, with a mean age of (8. 35 ± 5. 34) years. Totally 66. 67% of cases were treated for influenza, with two cases of non-standard medication (one case for a 2-month-old infant for treatment, and the other case for a 9-year-old child for prevention). Totally 83. 33% of ADR occurred within 2 d of administration, primarily manifesting as sleep disturbances, frequent crying, irritability, and delirium. Severe cases presented suicidal ideation and self-harming behaviour. In most cases, the symptoms were improved within 3 d after drug withdrawal. Conclusion: When prescribing oseltamivir clinically, vigilant monitoring for neuropsychiatric symptoms within the first 2 d of treatment is essential, with particular attention to potential suicidal risk in children. Immediate discontinuation is required upon onset of neuropsychiatric ADR. If the condition does not improve or worsens, medical attention should be sought immediately. Meanwhile, education on medication for caregivers is imperative. |
| Key words: oseltamivir neuropsychiatric system adverse drug reactions children |
